Madryn Asset Management, LP v. Trailmark Inc.

CourtDistrict Court, S.D. New York
DecidedMarch 30, 2024
Docket1:23-cv-03704
StatusUnknown

This text of Madryn Asset Management, LP v. Trailmark Inc. (Madryn Asset Management, LP v. Trailmark Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Madryn Asset Management, LP v. Trailmark Inc., (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ---------------------------------------------------------------------- X : MADRYN ASSET MANAGEMENT, LP, : : Petitioner, : : -v- : 23 Civ. 3704 (JPC) : TRAILMARK INC, : OPINION AND : ORDER Respondent. : : ---------------------------------------------------------------------- X

JOHN P. CRONAN, United States District Judge: Petitioner Madryn Asset Management, LP (“Madryn”) has petitioned to vacate an interim arbitration award on liability issued in favor of Respondent Trailmark, Inc. (“Trailmark”). Finding that the Court has jurisdiction to review the interim award and that there are no grounds to modify or vacate it, the Court denies the petition. I. Background A. Underlying Facts1 Madryn, an asset manager that creates and manages private funds for investors, was formed as a spin-out from now-defunct Visium Fund Management, LLC (“Visium”). Interim Award at 1-2; Petition at 2. In 2014, Visium retained Trailmark, a registered broker-dealer that acts as a placement agent, to help raise what would later become Madryn’s first fund, Madryn Health

1 The following facts are drawn from the subject advisory agreement, Dkt 17-1 (“Agreement”), the arbitrator’s Interim Award, Dkt. 17-26 (“Interim Award”), and the parties’ submissions—which include Madryn’s petition to vacate the arbitrator’s award, Dkt. 3 (“Petition”), Trailmark’s opposition, Dkt. 21 (“Opposition”), Madryn’s Reply, Dkt. 24 (“Reply”), and exhibits attached to their attorneys’ declarations, Dkts. 22 (“Miodonka Declaration”); 25 (“Bolla Declaration”). Partners, L.P. (“MHP”). Interim Award at 1; Petition at 2-3. After Visium’s collapse, Madryn assumed management responsibilities over MHP. Interim Award at 4; Petition at 2. At the time of the spin-out, Visium owed Trailmark placement agent fees and sought to have that obligation assumed by Madryn with a release from Trailmark. Interim Award at 4. That release gave Trailmark substantial leverage over Madryn—which needed Trailmark to continue as

a placement agent on MHP—as to the timing and terms of a new advisory agreement between them. Id. For instance, while Madryn preferred to push off the negotiation until after the spin- out, the Agreement was ultimately executed as part of the spin-out process, pursuant to Trailmark’s insistence. Id. at 5 n.4. During the negotiations, Trailmark proposed serving as Madryn’s exclusive placement agent for three Madryn “Health Partner” funds with the same compensation model for the first and second funds. Id. at 5. Trailmark further proposed that it earn fees for its services on the second fund based on funds raised from investors that participated in the first fund. Id. Despite Madryn’s objection particularly to the latter proposal, the parties included these terms in the Agreement, which was executed on January 21, 2017. Id. at 5-6.

Under the precise terms of the Agreement, Trailmark was to be the exclusive placement agent for MHP and any parallel or feeder vehicles (collectively defined as the “Fund”), with the parties’ mutual obligations as to MHP further extending to both “Fund II” and “Fund III.” Id. at 6; see also Agreement § 1. Under Section 9(a) of the Agreement, “Fund II” and “Fund III” are defined as “the first two funds following the Fund that will be expected to invest more than 75% of their capital pursuant to the Madryn Strategy,” which is, in turn, defined to include “investments in debt instruments, royalty interests, revenue interests, [etc.] . . . relating to pharmaceutical and healthcare companies, institutions or inventors.” Petition at 3 (citing Agreement § 9(a)(viii), (ix)). And pursuant to Section 9(m), Trailmark has the right to deem any “Off-Strategy Fund”—that is, a fund following the Fund or Fund II that is not expected to invest more than 75% of its capital pursuant to the Madryn Strategy—as “Fund II” or “Fund III” within thirty days of notice by Madryn of its intent to raise such a fund. Id. at 4 (citing Agreement § 9(m)). That subsection concludes: For the avoidance of doubt, any fund raised by Madryn following the Fund or Fund II, as applicable, that is expected to invest more than 75% of its capital pursuant to the Madryn Strategy, shall automatically be considered to be Fund II or Fund III, as applicable, subject to [Trailmark]’s ability to elect to cause an Off-Strategy Fund to be considered Fund II or Fund III, as applicable, for purposes of this Agreement.

Id. (citing Agreement § 9(m)). As for compensation, the Agreement entitles Trailmark to placement fees that are calculated based on the commitments made by investors to the funds, as well as fixed advisory fees. See Interim Award at 8 (discussing Agreement §§ 9(d), (e), and (i)). At the same time, the Agreement gives Madryn a “Fund III Limited Scope Right” to limit Trailmark’s right to commissions on those investors in Fund III who directly or through their advisors had previously taken meetings or substantive telephone calls with Madryn and may or may not have invested in Fund II but had not invested in Fund I. Id. (discussing Agreement § 2). MHP closed in December 2019 after it raised roughly $400 million. Id. at 9. Both Madryn and Trailmark expected that MHP would be followed by progressively larger successor funds, as that was the standard practice in the industry. Id. Indeed, Madryn projected an initial target of between $500 million and $600 million in assets under management for the next fund, Fund II. Id.; see Opposition at 5. The parties further expected that Fund II would be MHP II, as evidenced by Madryn’s corporate officers’ consistent reference to MHP II as “Fund II” in internal emails. Interim Award at 9 n.8, 28-30. Madryn began its preliminary work on MHP II in late 2019, even before the close of MHP, Id. at 9. Madryn hid this from Trailmark, however, as Madryn intended to replace Trailmark with Trailmark’s competitor, Campbell Lutyens & Co. (“CL”), and to negotiate a buyout of Trailmark. Id. at 10. From October 2019 until May 2021, Madryn met with CL roughly 20 times. Id.; see also Petition at 6 (“Madryn also internally considered retaining another placement agent—meeting with another candidate numerous times”). Madryn took active measures to conceal these meetings from Trailmark, including by using encrypted emails. Interim Award at 10. In May 2020, Madryn

and CL agreed in principle to terms for Madryn to retain CL as the placement agent for MHP II, and exchanged drafts of an engagement letter over the next two months. Id. at 11-12. But these discussions ultimately came to a halt. Id. In February 2021, Madryn reached out to Trailmark about “Fund II,” seeking to renegotiate the placement fee terms of the Agreement. Id. at 12; Petition at 6. Madryn explained that it could no longer afford Trailmark’s fees due to a change in its investor fee model, but when Trailmark asked twice in March 2021 to see Madryn’s financial models, Madryn failed to respond. Interim Award as 12-13. Instead, in May 2021, Madryn admitted that it did not want to work with Trailmark on MHP II and offered to buy Trailmark out of the Agreement. Id. at 13. Trailmark

made a counteroffer, and Madryn—believing that the size of the counteroffer indicated that Trailmark was simply unwilling to engage in such discussions—ignored it. Id. Meanwhile, Madryn resumed its work on MHP II. Id. at 13. And from March 2021 to July 2021, Madryn continued to discuss MHP II with investors, continued to refer to MHP II as “Fund II” internally, and continued to interview placement agents to replace Trailmark. Id. at 13-14. Trailmark next heard from Madryn on July 8, 2021, when Madryn sent Trailmark an email with the “exciting news” that it would be raising “Fund II.” Id. at 17. Much to Trailmark’s surprise, Madryn was referring not to MHP II, but rather to Madryn Select Opportunities LP (“MSO”). Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

First Options of Chicago, Inc. v. Kaplan
514 U.S. 938 (Supreme Court, 1995)
Fishoff v. Coty, Inc.
634 F.3d 647 (Second Circuit, 2011)
Schwartz v. Merrill Lynch & Co.
665 F.3d 444 (Second Circuit, 2011)
Westerbeke Corporation v. Daihatsu Motor Co., Ltd.
304 F.3d 200 (Second Circuit, 2002)
Oxford Health Plans LLC v. Sutter
133 S. Ct. 2064 (Supreme Court, 2013)
Zeiler v. Deitsch
500 F.3d 157 (Second Circuit, 2007)
T. CO METALS, LLC v. Dempsey Pipe & Supply, Inc.
592 F.3d 329 (Second Circuit, 2010)
Dalton v. Educational Testing Service
663 N.E.2d 289 (New York Court of Appeals, 1995)
511 West 232nd Owners Corp. v. Jennifer Realty Co.
773 N.E.2d 496 (New York Court of Appeals, 2002)
CSI Investment Partners II, L.P. v. Cendant Corp.
507 F. Supp. 2d 384 (S.D. New York, 2007)
Seneca Nation of Indians v. State of New York
988 F.3d 618 (Second Circuit, 2021)

Cite This Page — Counsel Stack

Bluebook (online)
Madryn Asset Management, LP v. Trailmark Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/madryn-asset-management-lp-v-trailmark-inc-nysd-2024.